Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder.

Garriock HA, Tanowitz M, Kraft JB, Dang VC, Peters EJ, Jenkins GD, Reinalda MS, McGrath PJ, von Zastrow M, Slager SL, Hamilton SP.

Am J Psychiatry. 2010 May;167(5):565-73. doi: 10.1176/appi.ajp.2009.08081167. Epub 2010 Mar 1.

2.

Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.

Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, Fava M, Bradley B, Ressler KJ, Nemeroff CB.

Arch Gen Psychiatry. 2010 Apr;67(4):369-79. doi: 10.1001/archgenpsychiatry.2010.18.

PMID:
20368512
3.

SLC6A4 variation and citalopram response.

Mrazek DA, Rush AJ, Biernacka JM, O'Kane DJ, Cunningham JM, Wieben ED, Schaid DJ, Drews MS, Courson VL, Snyder KA, Black JL 3rd, Weinshilboum RM.

Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 5;150B(3):341-51. doi: 10.1002/ajmg.b.30816.

4.

A genomewide association study of citalopram response in major depressive disorder.

Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, Reinalda MS, Slager SL, McGrath PJ, Hamilton SP.

Biol Psychiatry. 2010 Jan 15;67(2):133-8. doi: 10.1016/j.biopsych.2009.08.029.

5.

The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort.

Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ, Paddock S.

Biol Psychiatry. 2008 Jun 15;63(12):1103-10. doi: 10.1016/j.biopsych.2007.10.026. Epub 2008 Jan 11.

6.

SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report.

Shiroma PR, Drews MS, Geske JR, Mrazek DA.

Am J Geriatr Psychiatry. 2014 Nov;22(11):1140-8. doi: 10.1016/j.jagp.2013.02.012. Epub 2013 Aug 20.

7.

The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study.

Kocabas NA, Faghel C, Barreto M, Kasper S, Linotte S, Mendlewicz J, Noro M, Oswald P, Souery D, Zohar J, Massat I.

Int Clin Psychopharmacol. 2010 Jul;25(4):218-27. doi: 10.1097/YIC.0b013e328338b884.

PMID:
20531207
8.

Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder.

Cutler JA, Rush AJ, McMahon FJ, Laje G.

J Psychopharmacol. 2012 Mar;26(3):360-7. doi: 10.1177/0269881111434622. Epub 2012 Jan 26.

PMID:
22282879
9.

Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.

Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ.

Am J Psychiatry. 2007 Aug;164(8):1181-8.

PMID:
17671280
10.

Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression.

Poland RE, Lesser IM, Wan YJ, Gertsik L, Yao J, Raffel LJ, Lin KM, Myers HF.

Life Sci. 2013 May 30;92(20-21):967-70. doi: 10.1016/j.lfs.2013.03.009. Epub 2013 Apr 3.

11.

Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.

Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH, Smoller JW.

Arch Gen Psychiatry. 2007 Jun;64(6):689-97.

PMID:
17548750
12.

Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.

Adkins DE, Clark SL, Åberg K, Hettema JM, Bukszár J, McClay JL, Souza RP, van den Oord EJ.

Transl Psychiatry. 2012 Jul 3;2:e129. doi: 10.1038/tp.2012.57.

13.

Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.

Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP.

Biol Psychiatry. 2007 Mar 15;61(6):734-42. Epub 2006 Nov 21.

PMID:
17123473
14.

HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients.

Wang P, Lv Q, Mao Y, Zhang C, Bao C, Sun H, Chen H, Yi Z, Cai W, Fang Y.

J Affect Disord. 2018 Mar 1;228:222-228. doi: 10.1016/j.jad.2017.12.010. Epub 2017 Dec 7.

PMID:
29275155
15.
16.

Mu opioid receptor gene variants: lack of association with alcohol dependence.

Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D.

Mol Psychiatry. 1997 Oct-Nov;2(6):490-4.

PMID:
9399694
17.

Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.

Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, Fava M, Trivedi MH, Wisniewski SR, Laje G, Paddock S, McMahon FJ, Manji H, Lipsky RH.

Arch Gen Psychiatry. 2007 Jul;64(7):783-92.

PMID:
17606812
18.

MRP1 polymorphisms associated with citalopram response in patients with major depression.

Lee SH, Lee MS, Lee JH, Kim SW, Kang RH, Choi MJ, Park SJ, Kim SJ, Lee JM, Cole SP, Lee MG.

J Clin Psychopharmacol. 2010 Apr;30(2):116-25. doi: 10.1097/JCP.0b013e3181d2ef42.

PMID:
20520284
19.

Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D.

Fabbri C, Drago A, Serretti A.

Eur Neuropsychopharmacol. 2013 Jul;23(7):612-21. doi: 10.1016/j.euroneuro.2012.07.006. Epub 2012 Aug 11.

PMID:
22884879
20.

Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes.

Mitjans M, Gastó C, Catalán R, Fañanás L, Arias B.

J Psychopharmacol. 2012 Oct;26(10):1391-8. doi: 10.1177/0269881112454229. Epub 2012 Jul 23.

PMID:
22826533

Supplemental Content

Support Center